Previous 10 | Next 10 |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become. That means that penny stocks, which are riskier by nature, are finding their ...
Summary In their legal war, UTHR seems to have won a key battle as opposed to Liquidia. This has pushed back LQDA's launch by 18 months. I consider this a singular setback for the underdog. Liquidia's ( NASDAQ: LQDA ) Tyvaso competitor Yutrepia won a tentativ...
MannKind Corporation ( NASDAQ: MNKD ), a biotech focused on rare lung diseases, added ~10% in the pre-market trading Tuesday in reaction to its plans to further develop clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease. With the disc...
Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, C...
If you’re looking for the best penny stocks to buy now, you’ve got plenty to choose from. The best place to start is to put together a watch list. This article is about penny stocks to watch and a handful of names moving in the stock market today. We dive in and look at wh...
Summary Once a highly speculative, non-revenue generating biotech on the verge of bankruptcy MNKD has de-risked much of the previous market concerns over bankruptcy, debt and credit issues. Their flagship product sold under the brand name AFREZZA is the only FDA approved rapid act...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that ...
Image source: The Motley Fool. MannKind Corporation (NASDAQ: MNKD) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: MannKind Corporation (MNKD) Q2 2022 Earnings Call Transcript
MannKind Corp (MNKD) Q2 2022 Earnings Conference Call August 09, 2022, 17:00 ET Company Participants Michael Castagna - CEO & Director Steven Binder - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Thomas Smith - SVB...
News, Short Squeeze, Breakout and More Instantly...
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note issued to Mann Group LL...
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 million Total debt reduced since December 31, 2023 ...
Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through Dece...